Next Article in Journal
Treatment of Tuberculosis in South Kazakhstan: Clinical and Economical Aspects
Previous Article in Journal
Vitamin D Status and Its Seasonal Variations and Association With Parathyroid Hormone Concentration in Healthy Women in Riga
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

Lack of Association Between CYP17 Mspa1 Polymorphism and Prostate Cancer Risk: A Meta-Analysis of 14 494 Cases and 15 971 Controls

1
Department of Hematology, Affiliated Hospital of Nantong University
2
Department of Life Sciences, Nanjing Normal University
3
Central Laboratory of Nanjing First Hospital, Nanjing Medical University, China
*
Author to whom correspondence should be addressed.
Medicina 2013, 49(2), 9; https://doi.org/10.3390/medicina49020009
Received: 20 March 2012 / Accepted: 28 January 2013 / Published: 2 February 2013
Background and Objective. A T-to-C polymorphism that creates a recognition site for the MspA1 restriction enzyme in the 5’ promoter region of CYP17 has been implicated as a risk factor for prostate cancer. To date, many studies have evaluated associations between the CYP17 MspA1 polymorphism and prostate cancer risk; however, the results were controversial. Therefore, the aim of this study was to perform a meta-analysis to investigate the association between the CYP17 MspA1 polymorphism and the risk of prostate cancer. Material and Methods. By searching the Pubmed, Web of Science, ScienceDirect, EBSCO databases, 36 studies including 14 494 cases and 15 971 controls were collected. Odds ratios (ORs) with their 95% confidence intervals (CIs) were used to assess the strength of the association.
Results
. The overall results showed no significant association between the CYP17 MspA1 polymorphism and the risk of prostate cancer (OR, 1.07; 95% CI, 0.92–1.25 for A2/A2 vs. A1/A1; OR, 1.02; 95% CI, 0.92–1.12 for A1/A2 vs. A1/A1; OR, 1.07; 95% CI, 0.94–1.22 for A2/A2 vs. A1/A2+A1/A1; OR, 1.03; 95% CI, 0.93–1.14 for A1/A2+A2/A2 vs. A1/A1). In the stratified analysis according to ethnicity, no significant associations were observed in Asian, European, and African populations in all genetic models. In the stratified analysis by the source of controls and inpatients were found to have an increased risk of prostate cancer in all genetic models.
Conclusions
. The meta-analysis suggests that the CYP17 MspA1 polymorphism is unlikely to increase the risk of prostate cancer in a wide population.
Keywords: CYP17 MspA1 polymorphism; meta-analysis; prostate cancer CYP17 MspA1 polymorphism; meta-analysis; prostate cancer
MDPI and ACS Style

Song, G.; Gu, L.; Tian, F.; Bao, Q.; Tang, Z.; Wang, S. Lack of Association Between CYP17 Mspa1 Polymorphism and Prostate Cancer Risk: A Meta-Analysis of 14 494 Cases and 15 971 Controls. Medicina 2013, 49, 9.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop